Simponi Aria Coupons & Prices

Looking for a Simponi Aria coupon? Simponi Aria is the intravenous (IV) form of golimumab, a TNF-blocker biologic given as a 30-minute infusion for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. Because it is infused in a clinic or infusion center rather than picked up at a pharmacy counter, the way you pay for it is different from a typical prescription, and there is no generic golimumab on the market today. Below we explain how Simponi Aria works, how the manufacturer's savings program compares with an Rx.com cash coupon, what the biosimilars approved in 2026 could mean for cost, and the safety points to review with your doctor. For any medicine you do fill at a retail pharmacy, enter your ZIP above to see today's price at nearby pharmacies.

What is Simponi Aria and how does it work?

Simponi Aria is the brand name for golimumab given by intravenous infusion. It is a monoclonal antibody that blocks tumor necrosis factor alpha (TNF-alpha), a protein in the immune system that drives the inflammation, joint swelling, pain, and joint damage seen in certain autoimmune diseases. By binding TNF-alpha, Simponi Aria turns down that inflammatory signal. It belongs to the same broad class as Humira, Enbrel, Remicade, and Cimzia.

The FDA-approved uses on the current label are moderately to severely active rheumatoid arthritis in adults (used together with methotrexate), active psoriatic arthritis in patients 2 years and older, active ankylosing spondylitis in adults, and active polyarticular juvenile idiopathic arthritis in patients 2 years and older. Simponi Aria is given by a healthcare professional as a 30-minute IV infusion, dosed by body weight at week 0 and week 4, then every 8 weeks. Important: the IV form is not approved for ulcerative colitis. Only the under-the-skin injection, Simponi, carries that indication.

Simponi Aria cost: manufacturer savings card vs. an Rx.com cash coupon

Simponi Aria is an infused biologic, so it is usually billed through your medical benefit (the clinic or infusion center buys the drug and bills your plan), not through your pharmacy benefit. That means the price is set by your plan, the site of care, and the infusion facility's charges rather than by a pharmacy shelf price. What you owe can vary a lot depending on where you get infused, so ask the infusion center for a written cost estimate before your first appointment.

Your main cost tools, and how they differ:

• Manufacturer savings program. Johnson & Johnson runs an official copay savings program for Simponi Aria (information is on the manufacturer's own Simponi Aria site and through its J&J withMe patient support program). Programs like this are generally limited to people with commercial insurance, and eligibility, caps, and terms vary and change over time. People with Medicare, Medicaid, TRICARE, VA coverage, or no insurance are typically not eligible.
• Patient assistance. If you are uninsured or underinsured and cannot afford treatment, the Johnson & Johnson Patient Assistance Foundation and the J&J withMe support line can screen you for free-medicine or other assistance programs. Independent nonprofit foundations that help with autoimmune-disease copays are another route worth asking your rheumatology office about.
• An Rx.com cash coupon. Our free coupon is a cash-discount card accepted at retail pharmacies. It will not usually apply to a drug infused in a clinic, but it is useful for the rest of your regimen, including the methotrexate, folic acid, or other prescriptions often taken alongside Simponi Aria. Unlike a manufacturer card, it does not require commercial insurance, so it can be used if you are uninsured, on Medicare, or if a copay card is declined. Retail prices vary by pharmacy, so it is worth comparing before you fill: enter your ZIP above to see today's price at pharmacies near you.

You cannot combine a cash coupon with insurance on the same fill: at the counter you either run it through your plan or use the coupon as a cash payment, whichever is cheaper that day.

Is there a generic or biosimilar golimumab?

There is no true generic version of golimumab, because it is a biologic, not a simple small-molecule drug. Biologics get biosimilars instead of generics. In May 2026 the FDA approved the first golimumab biosimilars, golimumab-sldi, cleared as interchangeable and marketed as Immgolis Intri (the IV form, comparable to Simponi Aria) and Immgolis (the subcutaneous form, comparable to Simponi), from Bio-Thera Solutions and Accord BioPharma.

Being approved is not the same as being available. As of July 2026 neither product has launched in the United States, so Simponi Aria remains the only IV golimumab you can actually receive in a US infusion center. Accord has said it is targeting US availability by late 2026, but that timing is not guaranteed: Janssen sued Bio-Thera and Accord in March 2026 over 17 patents and has a motion pending that asks the court to block a launch, with a hearing expected in the fall of 2026. Depending on how that turns out, the launch could be delayed.

When biosimilars do launch, they typically create price competition and can lower what plans and patients pay over time. Ask your rheumatologist and your infusion center whether a golimumab biosimilar has become available and whether your plan prefers it. Do not switch products on your own; substitution of an infused biologic is a decision for your prescriber and your plan.

Alternatives and how Simponi Aria compares

Simponi Aria (IV golimumab) and Simponi (subcutaneous golimumab) contain the same active drug but are not interchangeable products: they have different dosing schedules, different approved uses (only the subcutaneous form is approved for ulcerative colitis), and different ways of being administered and billed. Simponi Aria is infused by a professional every 8 weeks after the starter doses; Simponi is a self-injection given at home.

If a TNF blocker is not the right fit, or if one stops working, rheumatologists commonly consider other options depending on your diagnosis:

• Other TNF blockers: Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab, also IV), Cimzia (certolizumab pegol)
• Biologics with a different target: Orencia (abatacept), Actemra (tocilizumab)
• Conventional DMARDs: methotrexate, which is often used with Simponi Aria in rheumatoid arthritis rather than instead of it, and which is available as a generic tablet (prices vary by pharmacy, so compare before you fill)

Adalimumab and infliximab have biosimilars on the US market (etanercept biosimilars are approved but not yet launched here), which is one reason your insurer may ask you to try one of them first. Which biologic is appropriate depends on your diagnosis, prior treatments, other health conditions, and your plan's coverage rules. Your rheumatologist decides that with you.

Safety: what to know before starting Simponi Aria

Simponi Aria carries a boxed warning, the FDA's strongest warning, covering two things. First, serious infections: because the drug suppresses part of the immune system, patients face a higher risk of serious infections that can lead to hospitalization or death, including tuberculosis (often reactivation of a hidden, latent infection), invasive fungal infections such as histoplasmosis and coccidioidomycosis, and other bacterial, viral, and opportunistic infections. Most reported cases occurred in people also taking immune-suppressing drugs such as methotrexate or corticosteroids. You must be tested for latent TB before starting, and treated for it if positive; testing continues during therapy. Treatment is stopped if a serious infection develops. Second, malignancy: lymphoma and other cancers, some fatal, have been reported in children and adolescents treated with TNF blockers, and a rare, aggressive cancer called hepatosplenic T-cell lymphoma has been reported with TNF blockers.

Other important label warnings include reactivation of hepatitis B in people who carry the virus, new or worsening congestive heart failure, demyelinating disease (such as multiple sclerosis, optic neuritis, or Guillain-Barre syndrome), low blood cell counts, lupus-like syndrome, and hypersensitivity or infusion reactions. Live vaccines should be avoided during treatment, and Simponi Aria should not be combined with other biologic DMARDs or with abatacept or anakinra. Call your doctor right away about fever, cough, night sweats, weight loss, unusual bruising or bleeding, new numbness or vision changes, or new swelling and shortness of breath. This page is general information, not medical advice. Review your full history, infections, and vaccination status with your healthcare provider before starting or continuing Simponi Aria.